Women treated with standard chemotherapy
Ovarian Cancer A U.S. clinical study showed that the combination treatment (Avastin) and chemotherapy significantly slows the progression of ovarian cancer. Dr. Robert Burger of Fox Chase Cancer Center in Philadelphia (Pennsylvania East), who led the research, explained that this Phase 3 clinical trial, the first of its kind, has shown that blocking the formation of tumor and blood vessels significantly improves survival without disease progression in women with ovarian cancer or peritoneal very difficult to treat.
“The results of this trial showed that Avastin is an acceptable initial treatment for patients suffering from advanced ovarian cancer,” he said in presenting the results at the annual conference of the American Society of Clinical Oncology (AUC0) meeting this weekend in Chicago (Illinois, North). (more…)
